X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
nvp-auy922 (77) 77
index medicus (76) 76
humans (75) 75
hsp90 heat-shock proteins - antagonists & inhibitors (66) 66
oncology (66) 66
auy922 (44) 44
heat shock proteins (43) 43
cancer (42) 42
cell line, tumor (42) 42
isoxazoles - pharmacology (36) 36
animals (35) 35
female (33) 33
resorcinols - pharmacology (33) 33
hsp90 heat-shock proteins - metabolism (31) 31
antineoplastic agents - pharmacology (29) 29
male (28) 28
hsp90 inhibitor (27) 27
hsp90 (26) 26
apoptosis (25) 25
apoptosis - drug effects (25) 25
heat shock protein 90 (23) 23
expression (22) 22
mice (22) 22
proteins (22) 22
cell proliferation - drug effects (20) 20
shock-protein 90 (20) 20
xenograft model antitumor assays (19) 19
growth (18) 18
analysis (17) 17
middle aged (16) 16
cell survival - drug effects (15) 15
chaperone (15) 15
aged (14) 14
antineoplastic agents - therapeutic use (14) 14
breast-cancer (14) 14
hsp90 inhibitors (14) 14
isoxazoles - administration & dosage (14) 14
resorcinols - administration & dosage (14) 14
adult (13) 13
antitumor-activity (13) 13
signal transduction - drug effects (13) 13
tumors (13) 13
cell biology (12) 12
treatment outcome (12) 12
angiogenesis (11) 11
article (11) 11
dose-response relationship, drug (11) 11
isoxazoles - therapeutic use (11) 11
kinases (11) 11
lung neoplasms - drug therapy (11) 11
pharmacology & pharmacy (11) 11
research (11) 11
resorcinols - therapeutic use (11) 11
survival (11) 11
therapy (11) 11
cancer therapies (10) 10
chemotherapy (10) 10
hsp90 protein (10) 10
lung cancer (10) 10
mice, nude (10) 10
mutation (10) 10
resistance (10) 10
breast cancer (9) 9
cancer cells (9) 9
care and treatment (9) 9
cell cycle (9) 9
clinical trials (9) 9
heat-shock-protein-90 (9) 9
inhibitors (9) 9
phase-i (9) 9
17-allylamino-17-demethoxygeldanamycin (8) 8
antineoplastic agents - administration & dosage (8) 8
antineoplastic agents - chemistry (8) 8
biochemistry & molecular biology (8) 8
blotting, western (8) 8
cancer research (8) 8
carcinoma, non-small-cell lung - drug therapy (8) 8
cell growth (8) 8
cell lines (8) 8
drug resistance, neoplasm (8) 8
gene expression regulation, neoplastic - drug effects (8) 8
hematology (8) 8
isoxazoles - chemistry (8) 8
molecular chaperone (8) 8
molecular targeted therapy (8) 8
radiotherapy (8) 8
solid tumors (8) 8
targeted therapy (8) 8
trastuzumab (8) 8
tumor cells, cultured (8) 8
tumor-cells (8) 8
benzoquinones - pharmacology (7) 7
breast neoplasms - drug therapy (7) 7
cell proliferation (7) 7
combination (7) 7
degradation (7) 7
disease models, animal (7) 7
drug resistance (7) 7
ganetespib (7) 7
health aspects (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 12/2018, Volume 24, Issue 24, pp. 6548 - 6555
Purpose: EGFR exon 20 insertions account for up to 10% of all EGFR mutations in lung adenocarcinomas, representing the third most common cluster of mutations.... 
GROWTH-FACTOR RECEPTOR | MUTANTS | AFATINIB | ONCOLOGY | CANCER | AUY922
Journal Article
BMB Reports, ISSN 1976-6696, 2018, Volume 51, Issue 12, pp. 660 - 665
Human epidermal growth factor receptor 2 (HER2) inhibitors, such as trastuzumab and lapatinib are used to treat HER2-positive breast and gastric cancers.... 
Lapatinib | Drug resistance | HER2 | Gastric cancer | AUY922
Journal Article
Oncotarget, ISSN 1949-2553, 2018, Volume 9, Issue 19, pp. 14828 - 14848
There is a lack of personalized treatment options for women with recurrent platinum-resistant ovarian cancer. Outside of bevacizumab and a group of poly... 
Gene signature | Ovarian | AUY922 | TCGA | Auranofin
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2010, Volume 46, Issue 3, pp. 678 - 684
NVP-AUY922, a potent heat shock protein (HSP) 90 inhibitor, downregulates the expression of many oncogenic proteins, including the human epidermal growth... 
Zirconium-89 | Biomarker | Breast cancer | HER2 | Positron emission tomography | Heat shock protein 90 | NVP-AUY922
Journal Article
BMB reports, ISSN 1976-6696, 12/2018, Volume 51, Issue 12, pp. 660 - 665
Human epidermal growth factor receptor 2 (HER2) inhibitors, such as trastuzumab and lapatinib are used to treat HER2-positive breast and gastric cancers.... 
Lapatinib | Drug resistance | HER2 | Gastric cancer | AUY922 | TRASTUZUMAB | BIOCHEMISTRY & MOLECULAR BIOLOGY | OXALIPLATIN | PROTEIN 90 INHIBITOR | CHEMOTHERAPY PLUS | NVP-AUY922 | CAPECITABINE | METASTATIC BREAST-CANCER | DEGRADATION | 17-AAG | TUMOR-GROWTH
Journal Article
International Journal of Cancer, ISSN 0020-7136, 05/2019, Volume 144, Issue 10, pp. 2613 - 2624
Hepatocellular carcinoma (HCC) is a highly malignant tumor that responds very poorly to existing therapies, most probably due to its extraordinary inter‐ and... 
HSP90 | AUY922 | Sorafenib | Mcl‐1 | HCC | NUPR1 | β‐Catenin | Luminespib | p53 | Mcl-1 | β-Catenin | APOPTOSIS | PANCREATIC-CANCER | KINASE | SENSITIVITY | MESENCHYMAL TRANSITION | NVP-AUY922 | HEAT-SHOCK PROTEINS | COLON-CANCER CELLS | ONCOLOGY | beta-Catenin | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Carcinoma, Hepatocellular - drug therapy | Caspases - metabolism | Aged, 80 and over | Adult | Female | Gene Expression Regulation, Neoplastic - drug effects | Liver Neoplasms - drug therapy | Small Molecule Libraries - therapeutic use | Transcriptome - drug effects | Mutation - genetics | Resorcinols - therapeutic use | beta Catenin - metabolism | Hep G2 Cells | Up-Regulation - drug effects | Animals | Mice, Nude | Liver Neoplasms - metabolism | Cell Line, Tumor | HSP90 Heat-Shock Proteins - metabolism | Aged | Isoxazoles - therapeutic use | Carcinoma, Hepatocellular - metabolism | Care and treatment | Carcinoma | Gene mutations | Liver | Analysis | Heat shock proteins | Drug therapy | Tumor proteins | Liver cirrhosis | Cancer | Cell proliferation | Hsp90 protein | p53 Protein | Xenotransplantation | Hepatocellular carcinoma | Tissues | Anticancer properties | Proteins | Specific heat | Liver cancer | Heterogeneity | Xenografts | Deoxyribonucleic acid--DNA | Therapeutic applications | Caspase | Hsp70 protein | Depletion | Inhibitors | Hepatocytes | Cell lines | Antitumor activity | Mutation | Viability | Tumors | Heat shock
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2018, Volume 29, Issue 10, pp. 2092 - 2097
Abstract Background There are currently no approved targeted therapies for non-small-cell lung cancer (NSCLC) patients with EGFR exon 20 insertions (ins20), a... 
MULTICENTER | Hsp90 inhibitor | NSCLC | OPEN-LABEL | PHASE-3 | DOCETAXEL | EGFR mutation | HETEROGENEITY | ONCOLOGY | AUY922 | SHOCK-PROTEIN 90 | luminespib | MUTATIONS | AFATINIB | EGFR exon 20 insertion | ERLOTINIB
Journal Article
Journal Article
Current Topics in Medicinal Chemistry, ISSN 1568-0266, 10/2016, Volume 16, Issue 25, pp. 2753 - 2764
Heat shock proteins (HSPs) present as a double edged sword. While they play an important role in maintaining protein homeostasis in a normal cell, cancer cells... 
HSP90 | N-Terminal | Inhibitor | Chaperone | Cancer | FDG-PET | CO-CHAPERONES | COMPLEX | CHEMISTRY, MEDICINAL | HEAT-SHOCK-PROTEIN-90 | MOLECULAR CHAPERONES | POSTTRANSLATIONAL MODIFICATIONS | INHIBITOR NVP-AUY922 | PHASE-I | BINDING
Journal Article
Oncology Letters, ISSN 1792-1074, 07/2016, Volume 12, Issue 1, pp. 387 - 392
Journal Article
MOLECULAR CANCER THERAPEUTICS, ISSN 1535-7163, 03/2019, Volume 18, Issue 3, pp. 531 - 540
HSP90 is involved in stability and function of cancer-related proteins. This study was conducted to define the MTD, safety, pharmacokinetics, pharmacodynamics,... 
POTENT ANTITUMOR-ACTIVITY | VITRO | HEAT-SHOCK PROTEINS | DOSE-ESCALATION | ONCOLOGY | AUY922 | OCULAR TOXICITY | AT13387 | PROTEIN 90 INHIBITOR | GASTROINTESTINAL STROMAL TUMORS | CANCER
Journal Article
Journal Article
by Gao, C and Peng, YN and Wang, HZ and Fang, SL and Zhang, M and Zhao, Q and Liu, J
CURRENT PHARMACEUTICAL DESIGN, ISSN 1381-6128, 2019, Volume 25, Issue 8, pp. 849 - 855
Heat shock protein 90 (Hsp90) plays an essential role in various physiological and pathological processes. It activates client proteins to participate in tumor... 
client protein | cancer treatment | CELLS | HSP90 MOLECULAR CHAPERONE | EFFICACY | ATPase | CRYSTAL-STRUCTURE | signaling pathway | RECEPTOR | NVP-AUY922 | 17-DMAG | IN-VITRO | inhibitor | RESISTANCE | PHARMACOLOGY & PHARMACY | EXPRESSION | Heat shock protein 90
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.